未经证实:头颈部癌后接受微血管重建的患者通常有几种合并症,手术后往往会出现并发症和住院时间延长。因此,近年来,在这些接受微血管重建的患者中,加速康复手术(ERAS)的应用受到了关注。ERAS是一种围手术期和术后护理概念,已多次显示出各种外科手术的有益结果,包括微血管重建.这项研究介绍了我们的ERAS协议用于头颈部癌症重建后的结果。
UNASSIGNED:我们根据2019年6月至2020年12月的ERAS方案对30名连续患者进行了前瞻性治疗,并将接受治疗的患者的结果与接受传统手术后恢复(TRAS)方案治疗的患者的结果进行了比较。我们基于ERAS协议的以下核心恢复要素:改善患者信息,目标导向液体治疗,微创手术,保留阿片类药物的多模式镇痛,早期行走,和预定义的功能放电标准。
UNASSIGNED:两组的基线特征相当。ERAS组的住院时间明显较短(13.1vs.20.3天,p<0.001),步行时间明显缩短(3.0天vs.6.4天,p<0.001),拔除鼻胃管的时间较短(13.3天vs.22.7天,p=0.05),和更少的气管造口术(10%与90%,p<0.001)。并发症没有差异,皮瓣存活,或两组之间30天的重新入院。
UNASSIGNED:在接受微血管重建的头颈部癌症患者中引入ERAS似乎是安全的,并且可以改善恢复。
未经评估:3.
UNASSIGNED: Patients undergoing microvascular reconstruction after head and neck cancer typically have several comorbidities, and the procedures are often followed by complications and prolonged hospitalization. Consequently, the application of enhanced recovery after surgery (ERAS) for these patients undergoing microvascular reconstruction has gained attention in recent years. ERAS is a peri- and postoperative care concept that has repeatedly shown beneficial results for a wide variety of surgical procedures, including microvascular reconstruction. This
study presents the results after the introduction of our ERAS protocol for head and neck cancer reconstruction.
UNASSIGNED: We prospectively treated 30 consecutive patients according to our ERAS protocol from June 2019 to December 2020 and compared the results of the treated patients with those of patients treated with our traditional recovery after surgery (TRAS) protocol. We are based on our ERAS protocol on the following core elements of recovery: improved patient information, goal-directed fluid therapy, minimally invasive surgery, opioid-sparing multimodal analgesia, early ambulation, and pre-defined functional discharge criteria.
UNASSIGNED: The baseline characteristics of the groups were comparable. The ERAS group had a significantly shorter length of stay (13.1 vs. 20.3 days, p < 0.001), significantly shorter time to ambulation (3.0 days vs. 6.4 days, p < 0.001), shorter time to removal of nasogastric tube (13.3 days vs. 22.7 days, p = 0.05), and fewer tracheostomies performed (10% vs. 90%, p < 0.001). There were no differences in complications, flap survival, or 30-day re-admissions between the two groups.
UNASSIGNED: The introduction of ERAS in patients with head and neck cancer undergoing microvascular reconstruction seems safe and results in improved recovery.
UNASSIGNED: 3.